Of the 105 NSCLC patients treated with ICIs, 35 (33%) were treated with anti-VEGF agents before ICIs (pre-anti-VEGF) and 70 (67%) patients were not treated with anti-VEGF agents before ICIs (no pre-anti-VEGF) (Figure 1). The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.